Organ Function Assays - Global Medical Devices Pipeline Assessment, 2019 - ResearchAndMarkets.com

The "Organ Function Assays - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.

This report provides an overview of Organ Function Assays currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Organ Function Assays pipeline products.

Scope

• Extensive coverage of the Organ Function Assays under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Organ Function Assays and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Organ Function Assays under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered

1 Table of Contents

2 Introduction

2.1 Organ Function Assays Overview

3 Products under Development

3.1 Organ Function Assays - Pipeline Products by Stage of Development

3.2 Organ Function Assays - Pipeline Products by Territory

3.3 Organ Function Assays - Pipeline Products by Regulatory Path

3.4 Organ Function Assays - Pipeline Products by Estimated Approval Date

3.5 Organ Function Assays - Ongoing Clinical Trials

4 Organ Function Assays - Pipeline Products under Development by Companies

4.1 Organ Function Assays Companies - Pipeline Products by Stage of Development

4.2 Organ Function Assays - Pipeline Products by Stage of Development

5 Organ Function Assays Companies and Product Overview

• Company Overview
• Pipeline Products & Ongoing Clinical Trials Overview

5.1 Boditech Med Inc.

5.2 China Medical Technologies Inc. (Inactive)

5.3 Cornell University

5.4 Daxor Corp.

5.5 DSX Therapeutics LLC

5.6 French National Institute of Health & Medical Research

5.7 HepQuant LLC

5.8 Humedics GmbH

5.9 Merck Millipore Corp.

5.10 Myriad Genetics Inc.

5.11 Proteome Sciences PLC

5.12 Radboud University Medical Centre

5.13 Schnellgen Inc.

6 Organ Function Assays - Recent Developments

6.1 Oct 01, 2019: Fortress Diagnostics announces 8m investment in new headquarters

6.2 Sep 25, 2019: Myriad Genetics expands Board of Directors with two additional members

6.3 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership

6.4 Aug 27, 2019: Chris Cournoyer joins CareDx Board of Directors

6.5 Aug 13, 2019: Myriad Genetics reports fiscal fourth-quarter and full-year 2019 financial results

6.6 Aug 01, 2019: CareDx reports second quarter 2019 results

6.7 Jul 29, 2019: Siemens Healthineers continues to drive growth forward

6.8 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers

6.9 Jul 02, 2019: Grace Colon succeeds Amy Abernethy on the CareDx Board

6.10 May 08, 2019: CareDx reports first quarter 2019 results

6.11 May 07, 2019: Myriad Genetics reports fiscal third-quarter 2019 financial results

6.12 May 02, 2019: Siemens Healthineers posts strong revenue and profit growth in the second quarter

6.13 Apr 04, 2019: HepQuant's Disease Severity Index (DSI) demonstrates hepatic functional improvement in high percentage of NASH patients treated with obeticholic acid: Results from INTERCEPT 747-117

6.14 Mar 06, 2019: CareDx reports fourth quarter and FY 2018 results

6.15 Mar 04, 2019: Daxor Announces Rise in Kit Sales and Files Form N-CSR For 2018

6.16 Feb 20, 2019: Keith Hoffman joins HepQuant as Clinical Lab Manager

6.17 Feb 14, 2019: First patient enrolled in a pivotal trial of the HepQuant SHUNT Liver Diagnostic Test

6.18 Feb 11, 2019: Siemens Healthineers to invest EUR 350 million in new Campus Forchheim

6.19 Feb 05, 2019: Myriad Genetics reports fiscal second-quarter 2019 financial results

6.20 Jan 23, 2019: Proteome Sciences: Year-end trading update

6.21 Jan 07, 2019: CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results

6.22 Dec 31, 2018: Myriad Genetics announced its former CEO Peter Durkee Meldrum passed away

6.23 Dec 17, 2018: CareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the FDA

6.24 Dec 04, 2018: 10 Billion Lab Tests and Growing: Siemens Healthineers Mass. Manufacturing Expansion Largely Completed

6.25 Dec 04, 2018: 10 billion lab tests and growing: Siemens Healthineers mass. manufacturing expansion largely completed

6.26 Nov 26, 2018: CareDx names Reginald Seeto, MB.BS, as president and chief business officer

6.27 Nov 26, 2018: CareDx strengthens executive leadership team with the appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer

6.28 Nov 09, 2018: HepQuant receives IDE approval from U.S. FDA to initiate clinical trial of the SHUNT Liver Diagnostic Kit

6.29 Nov 09, 2018: Mayo Clinic elects Kent Thielen, M.D., CEO of its Florida operations; Mayo's board of trustees also names two new members

6.30 Nov 08, 2018: CareDx reports third quarter results

6.31 Nov 06, 2018: Proteome Sciences: Trading update confirmation of preferred provider status

6.32 Nov 05, 2018: Siemens Healthineers with strong finish in fourth quarter, full year targets for fiscal 2018 achieved

For more information about this report visit https://www.researchandmarkets.com/r/lff34d

View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005837/en/